ABBISKO-B(02256): ABK3376 approved by the National Medical Products Administration for IND.
Hu Yu-B (02256) announced that its subsidiary, Shanghai Hu Yu Biomedical Technology Co., Ltd. (Hu Yu Medicine...
ABBISKO-B (02256) announced that its subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharmaceutical) has independently discovered and developed a new generation EGFR oral small molecule inhibitor, ABK3376, in collaboration with Shanghai Allist Pharmaceuticals Co., Ltd. The drug has been approved by the China National Medical Products Administration for its first phase I clinical trial in humans, for the treatment of non-small cell lung cancer with EGFR-C797S resistance mutation.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
